Validity and Usefulness of a Single-Item Measure of Patient-Reported Bother From Side Effects of Cancer Therapy

被引:66
作者
Pearman, Timothy P. [1 ,2 ,3 ]
Beaumont, Jennifer L. [1 ]
Mroczek, Daniel [1 ]
O'Connor, Mary [1 ]
Cella, David [1 ,2 ,4 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, 250 E Super,Ste 520, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Support Oncol, Chicago, IL 60611 USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Prevent & Control Res, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
cancer treatment; clinical trials; measurement science; oncology practice; outcomes; patient-reported outcomes (PROs); quality of life; RENAL-CELL CARCINOMA; CHRONIC MYELOID-LEUKEMIA; SELF-RATED HEALTH; FUNCTIONAL ASSESSMENT; SURVIVORSHIP STATISTICS; VALIDATION; SUNITINIB; PHYSICIAN; MORTALITY; PAZOPANIB;
D O I
10.1002/cncr.31133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The improving efficacy of cancer treatment has resulted in an increasing array of treatment-related symptoms and associated burdens imposed on individuals undergoing aggressive treatment of their disease. Often, clinical trials compare therapies that have different types, and severities, of adverse effects. Whether rated by clinicians or patients themselves, it can be difficult to know which side effect profile is more disruptive or bothersome to patients. A simple summary index of bother can help to adjudicate the variability in adverse effects across treatments being compared with each other. METHODS: Across 4 studies, a total of 5765 patients enrolled in cooperative group studies and industry-sponsored clinical trials were the subjects of the current study. Patients were diagnosed with a range of primary cancer sites, including bladder, brain, breast, colon/rectum, head/neck, hepatobiliary, kidney, lung, ovary, pancreas, and prostate as well as leukemia and lymphoma. All patients were administered the Functional Assessment of Cancer Therapy-General version (FACT-G). The single item "I am bothered by side effects of treatment" (GP5), rated on a 5-point Likert scale, is part of the FACT-G. To determine its validity as a useful summary measure from the patient perspective, it was correlated with individual and aggregated clinician-rated adverse events and patient reports of their general ability to enjoy life. RESULTS: Analyses of pharmaceutical trials demonstrated that mean GP5 scores ("I am bothered by side effects of treatment") significantly differed by maximum adverse event grade (P<.001) in all trials, with a clear trend toward increasing GP5 scores with level of increasing adverse event grade. Effect sizes ranged from 0.13 to 0.46. Analyses of cooperative group trials demonstrated a significant correlation between GP5 and item GF3 ("I am able to enjoy life") in the predicted direction. CONCLUSIONS: The single FACT-G item "I am bothered by side effects of treatment" is significantly associated with clinician-reported adverse events and with patients' ability to enjoy their lives. It has promise as an overall summary measure of the burden of a given set of treatment toxicities compared with another. Future research can identify the contribution of individual side effects compared with one another in terms of how each may contribute to overall bother. (C) 2017 American Cancer Society.
引用
收藏
页码:991 / 997
页数:7
相关论文
共 20 条
  • [1] Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update
    Aprile, Giuseppe
    Rihawi, Karim
    De Carlo, Elisa
    Sonis, Stephen T.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (41) : 11793 - 11803
  • [2] Impact of oxaliplatin-induced neuropathy: a patient perspective
    Bennett, Barbara K.
    Park, Susanna B.
    Lin, Cindy S. -Y.
    Friedlander, Michael L.
    Kiernan, Matthew C.
    Goldstein, David
    [J]. SUPPORTIVE CARE IN CANCER, 2012, 20 (11) : 2959 - 2967
  • [3] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    Cella, D.
    Escudier, B.
    Rini, B.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Motzer, R.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1571 - 1578
  • [4] Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer
    Cella, David
    Rosenbloom, Sarah K.
    Beaumont, Jennifer L.
    Yount, Susan E.
    Paul, Diane
    Hampton, Debra
    Abernethy, Amy P.
    Jacobsen, Paul B.
    Syrjala, Karen
    Von Roenn, Jamie H.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (03): : 268 - 278
  • [5] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
  • [6] Chang CH, 1997, PHYS MED REHABIL STA, V11, P397
  • [7] DeSalvo KB, 2011, OCHSNER J, V11, P232
  • [8] Cancer Treatment and Survivorship Statistics, 2014
    DeSantis, Carol E.
    Lin, Chun Chieh
    Mariotto, Angela B.
    Siegel, Rebecca L.
    Stein, Kevin D.
    Kramer, Joan L.
    Alteri, Rick
    Robbins, Anthony S.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (04) : 252 - 271
  • [9] Self-rated health and physician-rated health as independent predictors of mortality in elderly men
    Giltay, Erik J.
    Vollaard, Albert M.
    Kromhout, Daan
    [J]. AGE AND AGEING, 2012, 41 (02) : 165 - 171
  • [10] Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study
    Hahn, EA
    Glendenning, GA
    Sorensen, MV
    Hudgens, SA
    Druker, BJ
    Larson, RA
    O'Brien, SG
    Dobrez, DG
    Hensley, ML
    Cella, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2138 - 2146